Compounded GLP-1 FDA Crackdown in 2026: Current Status
Introduction
The FDA hasn’t banned compounded GLP-1s in 2026. The agency closed the 503B mass-compounding pathway for semaglutide copies in February 2025 and tirzepatide copies in early 2025 after both shortages were resolved. 503A patient-specific compounding stayed legal and remains the legal pathway for compounded semaglutide and tirzepatide today.
What’s actually escalated is enforcement against specific bad actors: pharmacies using salt forms, vendors selling research peptides labeled “not for human use,” and international shippers operating outside US licensing. The FDA has issued warning letters, import refusals, and worked with state boards on disciplinary actions, but the legal category of 503A patient-specific compounding remains intact.
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.
What Did the FDA Actually Do in 2025?
Two main actions:
Quick Answer: The FDA didn’t ban compounded GLP-1s in 2025 or 2026; the category remains legal under section 503A
Ended the semaglutide shortage on February 21, 2025 after court challenges resolved. This removed the legal basis under section 506(b) of the FDCA for 503B outsourcing facilities to compound copies of branded semaglutide.
Maintained the tirzepatide shortage resolution from October 2024. The agency declared the tirzepatide shortage resolved earlier and survived legal challenges in late 2024.
After both shortages resolved, 503B mass-compounding of semaglutide and tirzepatide copies wound down with a brief grace period for inventory.
503A patient-specific compounding wasn’t affected by the shortage resolution. Section 503A allows compounding for individual patients with valid prescriptions regardless of shortage status, as long as the compound isn’t essentially a copy of a commercially available product without documented clinical reason.
Did the FDA Ban Compounded GLP-1 in 2026?
No. The agency hasn’t issued a ban on the category. 503A patient-specific compounding of semaglutide and tirzepatide is legal in 2026 when:
The compound uses an active ingredient on the FDA-permitted bulk substances list (semaglutide base, tirzepatide base; not salts).
The pharmacy holds appropriate state licensure.
The prescription is patient-specific from a US-licensed prescriber in the patient’s state.
The compound isn’t essentially a copy of a commercially available product without a documented clinical difference (different dose, excipient sensitivity, weight-based titration, etc.).
The compound isn’t on the FDA’s demonstrably difficult to compound list.
These rules existed before the shortage and continue to apply.
What Enforcement Actions Have Actually Happened?
FDA enforcement on compounded GLP-1 since 2023 has included:
Warning letters to compounding pharmacies using salt forms or making unapproved claims.
Warning letters to telehealth platforms partnered with non-compliant pharmacies.
Import refusals on shipments of bulk semaglutide or tirzepatide API from non-FDA-registered foreign suppliers.
Consumer alerts about compounded GLP-1 adverse events and dosing errors.
FAERS adverse event monitoring documenting thousands of compounded GLP-1 adverse events including dosing-error hospitalizations and at least one cluster of deaths attributed to overdose.
The FDA has not done category-wide enforcement (i.e., shutting down compliant 503A pharmacies). The agency targets specific bad actors.
What About the FAERS Adverse Event Data?
FDA’s FAERS database has accumulated thousands of adverse event reports tied to compounded GLP-1 products between 2022 and 2025. The reports cluster in a few categories:
Dosing errors, particularly concentration confusion when patients drew the wrong volume from multi-dose vials.
Severe GI events including hospitalizations for dehydration and electrolyte disturbance.
Hypoglycemia in non-diabetic patients who confused insulin syringes with insulin dosing.
A documented cluster of deaths attributed to overdose errors.
Injection site infections from sterility failures.
The FAERS data isn’t a controlled comparison with branded GLP-1s. Branded Ozempic®, Wegovy®, Mounjaro®, and Zepbound® also generate adverse event reports. The signal in compounded products centers on dosing errors and quality variability rather than the molecule itself.
What About Lawsuits From Novo Nordisk and Eli Lilly?
Both manufacturers have pursued civil litigation against compounding pharmacies and telehealth platforms since 2023. The cases generally allege:
Trademark infringement (using brand names in marketing).
False advertising (claims of equivalence to FDA-approved products).
Selling salt forms misrepresented as the approved active ingredient.
Operating in violation of section 503A criteria.
Some cases have settled with consent decrees. Some have resulted in injunctions blocking specific products. Manufacturers have published lists of pharmacies and telehealth platforms they’ve taken action against.
Civil litigation is separate from FDA enforcement and operates on a different timeline. The cases haven’t ended the category but have constrained how compounding pharmacies and telehealth platforms market and operate.
What About State Board of Pharmacy Actions?
State boards have been active on compounded GLP-1 enforcement, often more so than the FDA. Boards have suspended or revoked licenses for:
Using salt forms (semaglutide sodium, tirzepatide acetate).
Mass-compounding without patient-specific prescriptions after the shortage resolved.
Shipping into states without nonresident pharmacy permits.
Sterility or potency failures on inspection.
USP <797> violations in compounding practices.
State board actions are public and searchable on each state board’s website. California, Texas, Florida, and New York boards have been the most active.
Key Takeaway: The FDA’s FAERS database has thousands of compounded GLP-1 adverse event reports since 2022
Is 503A Patient-specific Compounding Still Legal in 2026?
Yes. Section 503A of the FDCA permits a state-licensed pharmacy to compound a drug for an individual patient with a valid prescription when:
The active ingredient is on the FDA-permitted bulk substances list (semaglutide base and tirzepatide base both qualify).
The compound isn’t essentially a copy of a commercially available product, or there’s a documented clinical difference (different dose, excipient sensitivity, etc.).
The compound isn’t on the demonstrably difficult to compound list.
State licensure is current.
The prescription is from a US-licensed prescriber in the patient’s state.
These five conditions define the 503A safe harbor. Pharmacies meeting all five operate legally in 2026.
What’s Likely to Happen with FDA Enforcement in 2026?
Three patterns are visible:
Continued targeted enforcement against bad actors, especially salt-form vendors and unlicensed international shippers.
Possible action on the demonstrably difficult to compound list, which the FDA could in theory use to restrict GLP-1 compounding, though no formal proposal has moved through the rulemaking process as of May 2026.
Continued FAERS monitoring and consumer alerts about dosing errors and sterility events.
The FDA hasn’t signaled intent to end 503A patient-specific compounding of GLP-1s as a category. Doing so would require either statutory change (Congress) or adding the molecules to the demonstrably difficult to compound list, which is a slow process with public comment.
What Does This Mean for Patients in 2026?
Compliant 503A compounded semaglutide and tirzepatide remain available through state-licensed pharmacies. Patients can legally get prescriptions filled when the pharmacy and prescriber meet section 503A requirements.
Patients should avoid:
Salt-form products (semaglutide sodium, tirzepatide acetate).
Research-peptide vendors (research use only labeling).
International shippers.
Pharmacies without verifiable state licensure.
Sketchy telehealth operations without batch testing or pharmacist consultation.
TrimRx’s free assessment quiz routes patients to US-licensed 503A pharmacies that meet section 503A criteria, including documented batch testing and US shipping.
Will the Crackdown Intensify in 2027 or Beyond?
Possible. The FDA’s options include adding compounded GLP-1s to the demonstrably difficult to compound list, which would require formal rulemaking and is reversible by court action. Congress could legislate restrictions, which would be slower and harder. Manufacturer civil litigation will continue to constrain specific practices.
The most likely path is continued targeted enforcement against bad actors with the 503A patient-specific category remaining legal but increasingly scrutinized.
Bottom line: 503A patient-specific compounding requires documented clinical need post-shortage
FAQ
Is Compounded Semaglutide Illegal in 2026?
No, not as a category. 503A patient-specific compounding remains legal when the pharmacy meets section 503A requirements.
Is Compounded Tirzepatide Illegal in 2026?
No. Same answer. 503A patient-specific compounding is legal.
What Did the FDA Actually Ban?
The FDA didn’t ban compounded GLP-1s. The agency declared the shortages resolved, which ended the 503B mass-compounding pathway for copies. 503A continues.
What Happens to Pharmacies Caught Using Salt Forms?
State boards have suspended or revoked licenses. The FDA has issued warning letters. Manufacturers have pursued civil litigation. Salt-form use is not legal compounding under section 503A.
Will My Compounded GLP-1 Still Be Available in 2026?
Yes, if your pharmacy is a US-licensed 503A pharmacy using base API with valid prescriptions. Compliant pharmacies are operating normally.
How Do I Confirm My Pharmacy Is Compliant?
Verify the state board of pharmacy license is active, confirm 503A status in writing, ask for written confirmation of base API (not salts), and request batch testing certificates of analysis.
Did Eli Lilly or Novo Nordisk Shut Down Compounded GLP-1?
No. They’ve pursued civil litigation against specific bad actors and have publicly opposed compounded copies, but the category remains legal under section 503A.
Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.
Related Articles
Transforming Lives, One Step at a Time
Keep reading
GLP-1 Medications for Men Over 40: Testosterone, Metabolism, and Results
Weight loss for men over 40 operates under a different set of biological conditions than it did in your 20s or 30s, and GLP-1…
Long-Term Weight Loss Success on GLP-1: Habits That Actually Stick
GLP-1 medications are among the most effective weight loss tools ever developed, but they don’t produce identical long-term outcomes for everyone who takes them….
GLP-1 Maintenance vs Active Weight Loss: How Dosing Strategy Changes
Most of the conversation around GLP-1 medications focuses on the active weight loss phase: how fast results come, what side effects to expect, and…
